CAJ | 학술논문

对磷脂酰肌醇3-激酶（Phosphatidyl inositol 3-kinase，PI3K）抑制剂作为抗肿瘤药物的临床研究进展作一综述。 PI3K在细胞生长，增殖和凋亡等过程中起重要调节作用，与乳腺癌、卵巢癌、前列腺癌等肿瘤的发生发展密切相关。因此，PI3K已成为很有前途的癌症治疗靶标，超过10多种PI3K抑制剂作为抗肿瘤药物已进入临床研究。
대린지선기순3-격매（Phosphatidyl inositol 3-kinase，PI3K）억제제작위항종류약물적림상연구진전작일종술。 PI3K재세포생장，증식화조망등과정중기중요조절작용，여유선암、란소암、전렬선암등종류적발생발전밀절상관。인차，PI3K이성위흔유전도적암증치료파표，초과10다충PI3K억제제작위항종류약물이진입림상연구。
This review focused on the progress in clinical trials testing phosphatidyl inositol 3-kinase inhibitors (PI3Ki) as anticancer agents.PI3K is involved in various cellular processes and regulates many physiological func-tions including cell growth ,survival,amplification and apoptosis.The PI3K pathway is closely related to the occur-rence and development of breast cancer ,ovarian cancer,prostate cancer,etc.Therefore targeting PI3Ks is a promising approach for cancer therapy.Clinical trials of more than ten different PI 3K inhibitors as anticancer agents are under-way.